Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy.
Sasikumar PG, Ramachandra RK, Adurthi S, Dhudashiya AA, Vadlamani S, Vemula K, Vunnum S, Satyam LK, Samiulla DS, Subbarao K, Nair R, Shrimali R, Gowda N, Ramachandra M. Sasikumar PG, et al. Among authors: ramachandra rk, ramachandra m. Mol Cancer Ther. 2019 Jun;18(6):1081-1091. doi: 10.1158/1535-7163.MCT-18-0737. Epub 2019 Apr 23. Mol Cancer Ther. 2019. PMID: 31015307
ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity.
Holmström TH, Moilanen AM, Ikonen T, Björkman ML, Linnanen T, Wohlfahrt G, Karlsson S, Oksala R, Korjamo T, Samajdar S, Rajagopalan S, Chelur S, Narayanan K, Ramachandra RK, Mani J, Nair R, Gowda N, Anthony T, Dhodheri S, Mukherjee S, Ujjinamatada RK, Srinivas N, Ramachandra M, Kallio PJ. Holmström TH, et al. Among authors: ramachandra rk, ramachandra m. Mol Cancer Ther. 2019 Jan;18(1):28-38. doi: 10.1158/1535-7163.MCT-18-0204. Epub 2018 Oct 9. Mol Cancer Ther. 2019. PMID: 30301864
PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy.
Sasikumar PG, Sudarshan NS, Adurthi S, Ramachandra RK, Samiulla DS, Lakshminarasimhan A, Ramanathan A, Chandrasekhar T, Dhudashiya AA, Talapati SR, Gowda N, Palakolanu S, Mani J, Srinivasrao B, Joseph D, Kumar N, Nair R, Atreya HS, Gowda N, Ramachandra M. Sasikumar PG, et al. Among authors: ramachandra rk, ramachandra m. Commun Biol. 2021 Jun 8;4(1):699. doi: 10.1038/s42003-021-02191-1. Commun Biol. 2021. PMID: 34103659 Free PMC article.
Anti-PD-L1 peptide improves survival in sepsis.
Shindo Y, McDonough JS, Chang KC, Ramachandra M, Sasikumar PG, Hotchkiss RS. Shindo Y, et al. Among authors: ramachandra m. J Surg Res. 2017 Feb;208:33-39. doi: 10.1016/j.jss.2016.08.099. Epub 2016 Sep 8. J Surg Res. 2017. PMID: 27993215 Free PMC article.
Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases.
Murone M, Vaslin Chessex A, Attinger A, Ramachandra R, Shetty SJ, Daginakatte G, Sengupta S, Marappan S, Dhodheri S, Rigotti S, Bachhav Y, Brienza S, Traxler P, Lang M, Aguet M, Zoete V, Michielin O, Nicholas C, Johnson FM, Ramachandra M, McAllister A. Murone M, et al. Among authors: ramachandra r, ramachandra m. Mol Cancer Ther. 2016 Oct;15(10):2334-2343. doi: 10.1158/1535-7163.MCT-15-0974. Epub 2016 Jul 20. Mol Cancer Ther. 2016. PMID: 27439479
Structure-guided discovery of 1,3,5 tri-substituted benzenes as potent and selective matriptase inhibitors exhibiting in vivo antitumor efficacy.
Goswami R, Mukherjee S, Ghadiyaram C, Wohlfahrt G, Sistla RK, Nagaraj J, Satyam LK, Subbarao K, Palakurthy RK, Gopinath S, Krishnamurthy NR, Ikonen T, Moilanen A, Subramanya HS, Kallio P, Ramachandra M. Goswami R, et al. Among authors: ramachandra m. Bioorg Med Chem. 2014 Jun 15;22(12):3187-203. doi: 10.1016/j.bmc.2014.04.013. Epub 2014 Apr 18. Bioorg Med Chem. 2014. PMID: 24794746
86 results